1. Home
  2. LUCD vs ANIK Comparison

LUCD vs ANIK Comparison

Compare LUCD & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

HOLD

Current Price

$0.49

Market Cap

192.9M

Sector

Health Care

ML Signal

HOLD

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

SELL

Current Price

$19.96

Market Cap

200.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LUCD
ANIK
Founded
2018
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.9M
200.9M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
LUCD
ANIK
Price
$0.49
$19.96
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$4.00
★ $23.00
AVG Volume (30 Days)
★ 1.7M
85.3K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
★ 80.16
EPS
N/A
★ N/A
Revenue
$4,346,000.00
★ $112,819,000.00
Revenue This Year
$33.93
$7.82
Revenue Next Year
$165.18
$5.44
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 79.00
N/A
52 Week Low
$0.47
$9.01
52 Week High
$1.63
$22.88

Technical Indicators

Market Signals
Indicator
LUCD
ANIK
Relative Strength Index (RSI) 22.17 48.34
Support Level N/A $14.00
Resistance Level $1.09 $22.70
Average True Range (ATR) 0.07 0.83
MACD -0.01 0.07
Stochastic Oscillator 0.69 66.43

Price Performance

Historical Comparison
LUCD
ANIK

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Share on Social Networks: